Published in J Nucl Med on May 01, 2011
PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev (2014) 0.82
Regional particle size dependent deposition of inhaled aerosols in rats and mice. Inhal Toxicol (2011) 1.57
Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother (2007) 1.12
Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy (2007) 1.06
Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ERalpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates. J Am Chem Soc (2006) 0.93
Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol (2007) 0.91
Optimization of the preparation of fluorine-18-labeled steroid receptor ligands 16alpha-[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta-[18F]fluoro-5alpha-dihydrotestosterone (FDHT) as radiopharmaceuticals. J Labelled Comp Radiopharm (2014) 0.87
Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. J Nucl Med (2008) 0.86
A boronate-caged [¹⁸F]FLT probe for hydrogen peroxide detection using positron emission tomography. J Am Chem Soc (2014) 0.86
Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization. Mol Pharm (2010) 0.83
Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol (2012) 0.81
Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents. ACS Chem Biol (2010) 0.81
Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol (2008) 0.80
Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging (2015) 0.79
Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate. Antimicrob Agents Chemother (2005) 0.78
Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia. Cancer Biother Radiopharm (2006) 0.76
The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist. Biochem J (2012) 0.76
Operation of a radiopharmacy for a clinical trial. Semin Nucl Med (2010) 0.75
Molecular imaging update: advances in MI of the brain. J Nucl Med (2007) 0.75
Accepting the torch. Mol Imaging (2012) 0.75
Assessment of cancer-associated biomarkers by positron emission tomography: advances and challenges. Dis Markers (2002) 0.75
Join us in Salt Lake City. J Nucl Med (2010) 0.75
A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States. Appl Radiat Isot (2007) 0.75
Determination and control of volatilized 131I released in the preparation of 131I tositumomab dosages for radioimmunotherapy. J Am Pharm Assoc (2003) (2003) 0.75
Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash) (2002) 0.75
TLK-286. IDrugs (2004) 0.75
Components of a curriculum for molecular imaging scientists. J Nucl Med (2011) 0.75
Commentary: Prescriber beware: it is ill advised to administer compounded sincalide. J Nucl Med (2013) 0.75
CGMP for PET drugs: important steps to take now. J Nucl Med (2010) 0.75
Influence of impactor operating flow rate on particle size distribution of four jet nebulizers. Pharm Dev Technol (2007) 0.75